Comments
New warnings on Novartis MS pill in Europe and U.S
21.04.2012. | LONDON (Reuters) - European and U.S. regulators have backed the continued use of Novartis AG's multiple sclerosis pill Gilenya, one of the Swiss firm's top new drug hopes, but said on Friday the drug needed to carry stronger warnings on heart risks....
